Who is sponsoring NCT02916251?

NCT02916251 is sponsored by Zealand Pharma.

What drugs are being tested in NCT02916251?

Interventions in NCT02916251: ZP4207(dasiglucagon) glucagon analogue, Glucagon (Native glucagon).

What condition does NCT02916251 study?

NCT02916251 studies Diabetes Mellitus Type 1.

Is NCT02916251 still recruiting?

NCT02916251 is currently completed. Last updated 21 April 2017.

Last reviewed 2017-04-21 · How we verify

NCT02916251

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

ZP4207(Dasiglucagon) Administered to T1D Patients to Assess the PK and PD Compared to Marketed Glucagon

Completed Phase 2 Last updated 21 April 2017

What this trial tests

Phase 2 trial testing ZP4207(dasiglucagon) glucagon analogue in Diabetes Mellitus Type 1 in 38 participants. Completed in 5 April 2017.

Timeline

1 December 2016

Primary endpoint
5 April 2017

5 April 2017

Quick facts

Lead sponsor	Zealand Pharma
Phase	Phase 2
Status	Completed
Study type	INTERVENTIONAL
Allocation	randomized
Design	crossover
Masking	double
Primary purpose	treatment
Enrollment	38
Start date	1 December 2016
Primary completion	5 April 2017
Estimated completion	5 April 2017
Sites	1 location across Germany

Drugs / interventions tested

ZP4207(dasiglucagon) glucagon analogue — full drug profile →
Glucagon (Native glucagon) — full drug profile →

Conditions studied

Diabetes Mellitus Type 1 — all drugs for Diabetes Mellitus Type 1 →

Sponsor

Zealand Pharma — full company profile →

Who can join

Adults 18 to 64, any sex, with Diabetes Mellitus Type 1. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The trial is a single-centre, randomised, sequential, cross-over trial assessing pharmacokinetic and pharmacodynamic responses after micro-doses of ZP4207 (dasiglucagon\*) administered subcutaneously to patients with type 1 diabetes mellitus under euglycaemic and hypoglycaemic conditions and compared to marketed glucagon. \*dasiglucagon is the proposed International Nonproprietary Name (pINN) for ZP4207

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

Low doses of dasiglucagon consistently increase plasma glucose levels from hypoglycaemia and euglycaemia in people with type 1 diabetes mellitus.
Hövelmann U, Olsen MB, Mouritzen U, Lamers D, et al · · 2019 · cited 20× · PMID 30350477 · DOI 10.1111/dom.13562

Verify or expand the search:

Other recruiting trials for Diabetes Mellitus Type 1

Currently open trials in the same condition.

NCT07091318 — CBTi for the Treatment of Insomnia in Type 1 Diabetes · EARLY_PHASE1 · recruiting
NCT07320495 — Efficacy and Safety of the APGO Algorithm for Automated Insulin Delivery · NA · recruiting
NCT06936280 — Type 1 Diabetes and Diabetes Distress · NA · recruiting

Other Zealand Pharma trials

Trials by the same sponsor.

NCT07197944 — Efficacy And Safety Evaluation of Glepaglutide in Treatment of SBS · Phase 3 · recruiting
NCT07338214 — Investigating the Pharmacokinetics of Petrelintide Using Different Drug Product Concentrations · Phase 1 · completed
NCT07228403 — Efficacy and Safety Evaluation of Glepaglutide in Treatment of Short Bowel Syndrome · Phase 3 · enrolling by invitation
NCT06926842 — Efficacy and Safety of Petrelintide in Participants With Overweight or Obesity and Type 2 Diabetes (ZUPREME 2) · Phase 2 · active not recruiting
NCT07076030 — Pharmacokinetics of Petrelintide Following Administration to Participants With Impaired Renal Function · Phase 1 · completed

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT02916251 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Zealand Pharma
Last refreshed: 21 April 2017

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT02916251.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing